Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, leading to progressive neurological impairment. It accounts for approximately 1.8 million cases worldwide. There is a significant unmet clinical need for better therapies to treat the disease, as current treatment options, such as immunomodulators and monoclonal antibodies, have limitations in efficacy and safety. Furthermore, the growing focus on novel multiple sclerosis therapeutics, including remyelination agents and neuroprotective drugs, is likely to drive pipeline growth in the coming years. Advancements in biologics, gene therapy, and cell-based approaches are also shaping the future of multiple sclerosis drug development.
Major companies involved in the multiple sclerosis pipeline drugs market include Novartis Pharmaceuticals, Eli Lilly and Company, and others.
Leading drugs currently in the pipeline include Frexalimab, LY3541860, RO7121932, and others.
Advancements in biologics, gene therapy, and neuroprotective agents are driving the growth of the multiple sclerosis drug pipeline. Increasing prevalence, high unmet clinical need, and ongoing research in remyelination therapies are anticipated to support expansion in the coming years.
The Multiple Sclerosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into multiple sclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for multiple sclerosis. The multiple sclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with multiple sclerosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to multiple sclerosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Multiple sclerosis is a chronic disease in which the immune system mistakenly attacks the protective covering of nerve fibers in the central nervous system, causing inflammation and damage. It can lead to symptoms like muscle weakness, fatigue, and vision problems. The disease occurs in episodes of flare-ups, with progressive worsening over time.
Multiple sclerosis treatment aims to reduce disease activity and manage symptoms. Current therapies include disease-modifying drugs (DMDs) that slow progression, corticosteroids to manage relapses and symptomatic treatments. Emerging treatments focus on remyelination and neuroprotection, offering hope for improved outcomes.
The global multiple sclerosis drug pipeline is evolving rapidly, driven by the rising incidence of the disease. Over 1.8 million people are affected worldwide, with nearly 1 million cases in the United States. The United Kingdom reports over 150,000 individuals living with multiple sclerosis, while India has approximately 145,800 multiple sclerosis patients, with a prevalence rate of 11 per 100,000. These statistics highlight the increasing demand for innovative multiple sclerosis therapeutics.
This section of the report covers the analysis of multiple sclerosis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total multiple sclerosis clinical trials.
The drug molecule categories covered under the multiple sclerosis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and cell therapies. The multiple sclerosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for multiple sclerosis.
The EMR report for the multiple sclerosis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed multiple sclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in multiple sclerosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for multiple sclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of multiple sclerosis drug candidates.
The Phase 3 study, sponsored by Sanofi, aims to evaluate the efficacy and safety of Frexalimab in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The objective is to assess the drug's ability to delay disability progression compared to a placebo. The study is anticipated to be completed by March 2028, with an estimated 858 participants.
The drug LY3541860, sponsored by Eli Lilly and Company, is currently undergoing a Phase 2 study to assess its safety and efficacy in adult participants with relapsing multiple sclerosis. The primary objective is to evaluate its effect on slowing the occurrence of new T1 gadolinium-enhancing lesions. The study, expected to enroll approximately 200 participants, will be completed by August 2028.
Hoffmann-La Roche is a Phase 1 study, that aims to investigate the safety, tolerability, and pharmacokinetics of intravenous (IV) and subcutaneous (SC) RO7121932 in participants with multiple sclerosis. The study, which includes single and multiple ascending doses, is expected to be completed by December 2026, with an enrollment of around 129 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Multiple Sclerosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into multiple sclerosis collaborations, regulatory environments, and potential growth opportunities.
Global Multiple Sclerosis Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share